evening between 19 21 (PM-group) in a 1:1 ratio. If this also coincides with the peak in allergy symptoms, an optimal treatment effect should be expected. Pollen counts were not recorded. The adverse events recorded were of a magnitude and nature as seen in other studies of desloratadine and other antihistamines -. No statistically significant difference in efficacy was seen whether desloratadine was given in the morning or in the evening. These symptoms were recorded in a patient diary every morning (AM 12 hours reflective and AM last hour) and evening (PM 12 hours reflective and PM last hour) both at baseline and during the 2 weeks treatment period. A physical examination was performed at visit 1 and. All patients receiving at least one dose of study drug and having at least one post dose registration were included in the efficacy analysis (intention-to-treat, ITT and confirmatory analysis were based on evaluable patients with no protocol violations.
All adverse events were recorded. Evening dosing of this antihistamine may be expected to give better symptom relief than morning dosing on peak morning symptoms.
Elverum skysstasjon adresse, Elverum rr, Ark elverum,
It would have been difficult to keep patients in the Nordic countries off medication for more than one day in addition to any washout period during the pollen season. It seems likely that this exposure would influence the symptoms. Weitere Informationen zu unseren Cookies und dazu, wie du die Kontrolle darüber behältst, findest du hier: Cookie-Richtlinie. This difference may partly be due to patient selection. Visit 1 was at day 0 at the start of baseline, visit 2 after one week and visit 3 after two weeks. Baseline symptoms were recorded in the evening at day 0 and the following morning (day 1) after which the patients started taking the study medication as randomized. The exclusion criteria were: pulmonary disease, perennial rhinitis, sinusitis, rhinitis medicamentosa, pollen desensitization during the last 6 months, respiratory tract infection within the last two weeks, structural nasal abnormalities (including polyps use of oral, nasal, ocular decongestants, corticosteroids in any form (except mild dermatological group. The following symptoms were assessed using a scale from 0 to 3 (0none, 1mild, 2moderate, 3severe rhinorrhea, nasal congestion, sneezing, itching nose and eye symptoms (itching, burning, tearing, redness). OB participated as principal investigator in Sweden and enrolled most patients in the study. The best effect of mequitazine was obtained after evening dosing (12 hours before peak of symptoms) compared to morning dosing (24 hours before peak of symptoms). Since nasal itching had shown little circadian rhythm in these studies, this symptom was omitted from the TSS.